Abstract
The immune response to live-attenuated Francisella tularensis vaccine and its host evasion mechanisms are incompletely understood. Using RNA-Seq and LC–MS on samples collected pre-vaccination and at days 1, 2, 7, and 14 post-vaccination, we identified differentially expressed genes in PBMCs, metabolites in serum, enriched pathways, and metabolites that correlated with T cell and B cell responses, or gene expression modules. While an early activation of interferon α/β signaling was observed, several innate immune signaling pathways including TLR, TNF, NF-κB, and NOD-like receptor signaling and key inflammatory cytokines such as Il-1α, Il-1β, and TNF typically activated following infection were suppressed. The NF-κB pathway was the most impacted and the likely route of attack. Plasma cells, immunoglobulin, and B cell signatures were evident by day 7. MHC I antigen presentation was more actively up-regulated first followed by MHC II which coincided with the emergence of humoral immune signatures. Metabolomics analysis showed that glycolysis and TCA cycle-related metabolites were perturbed including a decline in pyruvate. Correlation networks that provide hypotheses on the interplay between changes in innate immune, T cell, and B cell gene expression signatures and metabolites are provided. Results demonstrate the utility of transcriptomics and metabolomics for better understanding molecular mechanisms of vaccine response and potential host–pathogen interactions.
Highlights
Francisella tularensis is a highly pathogenic, Gram-negative bacterium and is listed as a categoryA bioterrorism agent (Dennis et al, 2001)
The DVC-live vaccine strain (LVS) vaccine recipients were selected for this study as the DVC-LVS vaccine was generated from the latest lot of tularemia vaccine manufactured in accordance with current good manufacturing practices (CGMPs)
High-dimensional measurements of gene expression and metabolites were obtained over five time points from 10 subjects who received the DVC-LVS vaccine [1]
Summary
Francisella tularensis is a highly pathogenic, Gram-negative bacterium and is listed as a category. A bioterrorism agent (Dennis et al, 2001). We previously conducted a Phase 2 trial of two vaccines against F. tularensis, DVC-LVS and USAMRIID-LVS, which were based on two different lots of the same live vaccine strain. The clinical trial confirmed that both vaccines were safe and resulted in high rates of seroconversion The molecular mechanisms underlying these seroconversions are not well understood. F. tularensis pathogenesis is enhanced by the bacterium’s ability to suppress host innate immune responses [2]. The mechanisms used by the bacterium to achieve this suppression are actively being researched
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.